Sarepta Therapeutics Stock News

CNBC's Meg Tirrell joins 'Power Lunch' to discuss the Sarepta's gene therapy for muscular dystrophy, and why the stock is taking a tumble over doubts around Sarepta receiving FDA approval.

A report raised questions about the chances for approval of the company's gene therapy to treat Duchenne muscular dystrophy.

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares took a beating Thursday as Stat News reported that reviewers at the US Food and Drug Administration (FDA) were leaning toward rejecting a closely watched

Several FDA staffers were leaning toward rejecting a highly watched gene therapy from Sareptas, according to a report Thursday that sent SRPT stock into a dive. The post Sarepta Tumbles As Report Of I

Sarepta Therapeutics (NASDAQ: SRPT ) stock is taking a beating on Thursday following reports that the FDA was considering rejecting one of its drugs. According to these reports, regulators at the FDA

An experimental new gene therapy from Sarepta Therapeutics has an upcoming date with the Food and Drug Administration and a panel of independent experts. An approval decision coming in June could exte

Citi analyst Neena Bitritto-Garg initiates coverage on shares of Sarepta with a Buy rating.

Axsome already has two approved drugs and could add two more in the near future. Sarepta has significant growth opportunities with its rare-disease drugs.

The middle of March may be when many people celebrate St. Patrick's Day, but it was an unlucky time for Sarepta Therapeutics (NASDAQ: SRPT). Unfortunately, the United States Food and Drug Administrati

Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the n

Sarepta Therapeutics' (SRPT) shares plunged almost 20% as the FDA decides to hold an advisory meeting for the BLA of its lead gene therapy candidate SRP-9001.

Sarepta Therapeutics (NASDAQ: SRPT ) stock is sliding lower on Friday after the company announced an advisory committee meeting with the FDA. According to a press release, the company will meet with t

In a surprise decision, the FDA will hold an advisory committee to discuss Sarepta's gene therapy, and SRPT stock tanked Friday. The post Sarepta Crashes On An Unexpected Roadblock For Its Gene Therap

Sarepta Therapeutics Inc. SRPT shares plummeted in the extended session Thursday after the Food and Drug Administration contradicted the biotech company and said it required an advisory committee meet

Check out these 2 biotech stocks in the stock market today.